Invention Grant
- Patent Title: Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors
-
Application No.: US17003356Application Date: 2020-08-26
-
Publication No.: US11325917B2Publication Date: 2022-05-10
- Inventor: David Joseph Guerin , Kenneth W. Bair , Justin A. Caravella , Stephanos Ioannidis , David R. Lancia, Jr. , Hongbin Li , Steven Mischke , Pui Yee Ng , David Richard , Shawn E. R. Schiller , Tatiana Shelekhin , Zhongguo Wang
- Applicant: Valo Health, Inc.
- Applicant Address: US MA Boston
- Assignee: Valo Health, Inc.
- Current Assignee: Valo Health, Inc.
- Current Assignee Address: US MA Boston
- Agency: Barnes & Thornburg LLP
- Agent Aisha R. Hasan; Ryan L. Marshall
- Main IPC: C07D495/04
- IPC: C07D495/04
Abstract:
The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula: (I), where R1, R2, R3, R4, R4′, R5, R6, X, and n are described herein.
Public/Granted literature
- US20210047343A1 THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS Public/Granted day:2021-02-18
Information query
